Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 12, 2010, Pages 1233-1240

  Briesacher, Becky A ^a   Andrade, Susan E ^a   Harrold, Leslie R ^a   Fouayzi, Hassan ^a   Yood, Robert A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonates; Medication adherence; Osteoporosis; Osteoporotic fractures; Patient compliance

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK; TIME SERIES ANALYSIS;

BONE DENSITY CONSERVATION AGENTS; DATABASES, FACTUAL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS;

EID: 78649494854     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2048     Document Type: Article

References (31)

1. Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone 2007; 41: 882-887.
2. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414-2419.
3. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965-968.
4. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-550.
5. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249.
6. Delmas PD, Recker RR, Chesnut CH, 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-798.
7. Boniva Product. Labelling. v3.13 vol; March 2005.
8. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-1322.
9. Weiss TW, Henderson SC, McHorney CA, et al. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007; 23: 2193-2203.
10. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. American Journal of Medicine 2010; 123(3): 275-280.
11. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006; 22: 2383-2391.
12. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-354.
13. Blouin J, Dragomir A, Ste-Marie LG, et al. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 2007; 92: 887-894.
14. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17: 922-928.
15. Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236-242.
16. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-861.
17. MarketScan Research Databases User Guide and Database Dictionary. Ann Arbor, MI, Thomson Medstat: 2006.
18. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 437-447.
19. Andrade SE, Gurwitz JH, Chan KA, et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol 2002; 55: 310-313.
20. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev 2000; 21: 7-28.
21. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res 2001; 36: 180-193.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
23. Gibson TB, Mark TL, McGuigan KA, et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006; 12: 509-517.
24. Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001; 16: 1863-1870.
25. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002; 8: 276-279.
26. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, Houghton Mifflin Company: 2002.
27. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
28. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119: S12-S17.
29. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
30. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905.
31. Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008; 23: 1815-1821.